Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide +/- Olaparib in MGMT-Methylated Triple Negative Breast Cancer
NCT05128734Phase 2Not yet recruiting
- Sponsor
- American Health Staffing Group
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of temozolomide, olaparib in triple-negative breast cancer (TNBC), sponsored by American Health Staffing Group. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
temozolomideolaparib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05128734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05128734.